PharmaSector - 29apr19
PharmaSector - 29apr19
PharmaSector - 29apr19
April 2019
TABLE OF CONTENTS
❑ Bibliography
Global Medicine Spending | Trend
During the past decade, worldwide pharmaceutical spending have witnessed growth to over US$ 1 trln. Growth in
spending is attributed to market expansion in emerging countries and favorable demographics including an ageing
population in developed nations. Such trends are likely to continue over the coming years with global pharmaceutical
market growing to US$ 1.5 trln by 2021.
Pharmaceutical | Global Predictions
Growth from new products and pricing shifts will be Cost-containment measures and less growth
moderated by loss of exclusivity in the U.S. and by cost- from new products in Europe contribute to
containment measures worldwide. slower growth of 1-4%, compared to the 4.7%
compound annual growth seen over the past
five years that was significantly lifted by
spending from new products.
Global Drug Market
Top 15 Therapy Areas
Oncology therapy area is by far the largest in the pharma world with $107 billion in sales in 2017. It’s also projected to
maintain its dominance going forward, growing at an impressive 12.2% CAGR to $233 billion by 2024. Next, while sales in
cancer-related drugs will be the most in absolute terms, the fastest growing treatment area is actually in
immunosuppressants – a segment of drugs that make a body less likely to reject a transplanted organ, such as a liver, heart,
or kidney.
Pakistan | Industry Players’ Mix
There are approximately 650 companies operating in the Pakistani
pharmaceutical market, out of which less than 30 are multinational Market Composition | Sale Value
companies. The pharmaceutical industry contributes approximately ~1% to
the GDP of Pakistan annually. 33%
There are around 9,000 actively marketed drugs in Pakistan sold at licensed
pharmacies on prescription. In addition, there is a large segment of Over the
Counter (OTC) products e.g., multivitamins, pain, cold and flu relief.
67%
Name of Pharma Company Ranking National / MNC Listing Status
GlaxoSmithKline Pakistan Limited 1 MNC Listed MNC National
Getz Pharma (Private) Limited 2 National Unlisted
Sami Pharmaceutical (Private) Limited 3 National Unlisted Market Composition | No. of
Abbott Laboratories Pakistan Limited 4 MNC Listed
Companies
Martin Dow Pharmaceuticals (Pakistan) Limited 5 National Unlisted 3%
Product
Units FY14 FY15 FY16 FY17 FY18 FY19*
Category
Tablets 000 Nos 25,363,352 26,535,885 23,238,358 29,014,742 27,802,617 27,899,018
Syrups 000 Ltrs 91,139 98,996 108,342 117,084 112,637 104,916
Capsules 000 Nos 2,644,465 3,098,139 3,398,609 3,497,716 5,149,828 3,397,565
Injections 000 Nos 783,611 885,732 999,207 1,212,658 1,622,228 1,205,529
Ointments 000 Kgs 2,575 2,788 3,106 3,970 3,786 3,312
Galenicals 000 Ltrs 64 75 46 343 371 44
Source: Pakistan Bureau of Statistics
Pakistan | Revenue
Pharma Revenue | Trend
Total Revenue of the industry is on the rise – with GSK
140 50%
and Abbott contributing 50% of the Total revenue of
120
listed companies. 100
40%
PKR Mln
80 30%
In Mar2017, GSK Health Care was formed as a result of 60 20%
the demerger of Consumer Healthcare business of 40
GlaxoSmithKline Pakistan Limited. In 2018 GSK Health 10%
20
Care witnessed an increase of ~80% in Revenue. - 0%
2014 2015 2016 2017 2018
Revenue Growth %
┼ : Strengths
─ : Risks
Bibliography
1. Pakistan Pharmaceutical Industry | MAT Q1’18 Report | IMSHealth
2. Pakistan Bureau of Statistics, Government of Pakistan | Industry | Quantum Index of Large Scale Manufacturing
Industries (QIM)
3. Drug Pricing Policy-2015 & 18 issued by the Drug Authority of Pakistan with the approval of its Policy Board
and the Federal
4. PACRA’s in-house research and database – A sample of players representing approx. 33% of the market share